Brookfield Asset Management’s private equity arm and Caisse de dépôt et placement du Québec (CDPQ) are in advanced discussions to acquire Antylia Scientific from private equity firm GTCR, according to a report by Bloomberg citing sources familiar with the matter. The deal, which could value the life sciences diagnostics provider at approximately $1.4bn, remains confidential, with representatives from Brookfield, CDPQ, and GTCR reportedly declining to comment. Formerly known as Cole-Parmer, Antylia Scientific supplies biopharma, environmental, and life sciences companies, according to its website.
Read the full article: Brookfield, CDPQ Eye $1.4B Antylia Scientific Deal //
Source: https://www.privateequitywire.co.uk/brookfield-cdpq-eye-1-4bn-antylia-scientific-deal/